Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GE-145 (AN113111) Injection, Ioforminol, AH113111
GE-145 · 1 trial · 3 indications
Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.
| Arm | Type | Description |
|---|---|---|
| GE 145 320mg I/ml injection | EXPERIMENTAL | - |
| Iopamidol 370mg I/ml injection | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GE-145 | DRUG | GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration. |
Inclusion Criteria: * Males and females 65 years of age with cardiovascular disease who are referred for a coronary catheterization procedure with or without PCI. * The subject has at least one of the following comorbidities: * 1\) Chronic renal insufficiency, (eGFR \<60 but 15 mL/min/1.73 m2 accor...
GE-145 is an investigational small molecule contrast agent being developed by GE HealthCare Technologies Inc. for use in imaging procedures. It is formulated as an injectable agent and has been studied in patients with chronic renal insufficiency, a condition in which kidney function is reduced. GE-145 is also known as GE-145 (AN113111) Injection.
GE-145 is being studied as an injectable contrast agent for imaging in patients with chronic renal insufficiency. Its development focuses on use during coronary procedures in patients whose reduced kidney function makes contrast selection important. The Phase 2 program enrolled patients with chronic renal insufficiency, diabetes mellitus, and congestive heart failure.
GE-145 is developed by GE HealthCare Technologies Inc., which trades on the Nasdaq under the ticker GEHC. The company is the sponsor of the clinical program evaluating the agent. GE-145 is also referred to as GE-145 (AN113111) Injection.
GE-145 is in Phase 2 development. It is an investigational agent and has not been approved by the FDA. The Phase 2 study evaluating GE-145 has been completed, and no trials of the agent are currently listed as active.
GE-145 has been evaluated in one completed Phase 2 trial, NCT01252810, titled Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure. The randomized, double-blind, active-controlled study enrolled 284 participants aged 65 years and older in the United States.
Yes. GE-145 (AN113111) Injection is an alternative name for GE-145, the investigational contrast agent developed by GE HealthCare Technologies Inc. Both names refer to the same small molecule program studied in patients with chronic renal insufficiency undergoing coronary procedures.